Is CRISPR Therapeutics a Buy in the New Bull Market?
CRISPR Therapeutics (NASDAQ: CRSP) soared 54% last year as growth stocks rallied and the company itself moved toward an important milestone: the approval of its very first product. The gene editing specialist won the world's first nod for a CRISPR-based gene editing therapy back in November when the U.K. authorized Casgevy for sickle cell disease and beta thalassemia. Then the U.S. went on to approve the product for both blood disorders too.
What this means is CRISPR Therapeutics this year should start reporting its first product revenue. So, we're actually right at the start of the biotech's growth story -- a story that should deepen as the company advances other candidates through its pipeline. Meanwhile, the overall market has reached into bull territory, and this generally supports growth stocks. So, is CRISPR Therapeutics a buy in the new bull market? Let's find out.
Image source: Getty Images.
Source Fool.com
